Haleon (LON:HLN) Price Target Lowered to GBX 315 at JPMorgan Chase & Co.

Haleon (LON:HLN – Get Free Report) had its price target dropped by equities research analysts at JPMorgan Chase & Co. from GBX 335 to GBX 315 in a research note issued on Thursday,London Stock Exchange reports. The firm currently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential downside of 9.59% from the company’s current price.

Other research analysts have also issued reports about the company. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 370 price target on shares of Haleon in a report on Thursday, April 30th. Jefferies Financial Group lowered their price objective on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Berenberg Bank reiterated a “buy” rating and set a GBX 512 target price on shares of Haleon in a research note on Thursday, April 30th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 395.33.

Get Haleon alerts:

View Our Latest Stock Analysis on HLN

Haleon Price Performance

Shares of LON:HLN opened at GBX 348.40 on Thursday. The business has a 50 day moving average price of GBX 338.82 and a 200 day moving average price of GBX 364.11. Haleon has a twelve month low of GBX 317.80 and a twelve month high of GBX 416.10. The company has a market cap of £30.82 billion, a price-to-earnings ratio of 18.83, a PEG ratio of 1.49 and a beta of 0.25. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26.

Haleon Company Profile

(Get Free Report)

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.

See Also

• Five stocks we like better than Haleon
• 2 Space and Defense Stocks Turning Backlogs Into Revenue Growth
• Energy Fuels Just Made a Bold Bet on Rare Earth Magnets
• Washington’s Quantum Push Puts IBM and IonQ on the Throne
• FedEx’s Earnings Drop May Be Missing the Bigger Freight Story

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.